SANTA CLARA, Calif., Nov. 17 /PRNewswire-FirstCall/ -- XenoPort, Inc. today announced that it will provide access via the world wide web to its Lazard Capital Markets Life Science Conference presentation. The live presentation will occur at 3:30 p.m. Eastern Time on Tuesday, November 29, 2005. A replay of the presentation will be available for up to one week.
To access the presentation via the web, please go to www.XenoPort.com. Please connect to the company’s website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort’s most advanced product candidate, XP13512, has successfully completed a Phase 2b clinical trial for the treatment of restless legs syndrome, or RLS, and a Phase 2a clinical trial for the management of post-herpetic neuralgia. XenoPort has also completed an initial Phase 1 clinical trial of XP19986, a Transported Prodrug of R-baclofen. This trial demonstrated that XP19986 was suitable for twice-a-day dosing and was well tolerated with few adverse events at the doses tested.
To learn more about XenoPort, please visit the web site at www.XenoPort.com.
NOTE: XenoPort is a registered U.S. trademark.
Source Code: XNPT2G
XenoPort, Inc.
CONTACT: Jackie Cossmon of XenoPort, Inc., +1-408-616-7220, orir@XenoPort.com
Web site: http://www.xenoport.com/